膀胱癌的传统和创新成像技术:技术与应用

封面图片

如何引用文章

详细

这篇叙述性综述旨在描述成像技术在膀胱癌评估中的现状,其中考虑到了超声检查(US)、计算机断层扫描尿路造影(CTU)和磁共振成像(MRI)等传统技术,以及对比增强超声检查(CEUS)和双能量计算机断层扫描(DECT)等新型技术。文章首先介绍了膀胱的解剖结构,以了解正常的影像学表现,并结合流行病学、临床、分类和治疗介绍了膀胱癌的主要特征。随后,文章讨论了成像技术的作用,并解释了每种成像方式在膀胱癌评估中的技术和应用。影像学在膀胱癌的检测和分期中起着至关重要的作用。尤其是磁共振成像的作用正在不断扩大,因为它能利用膀胱成像报告和数据系 统(VI-RADS)以及 CTU 和 US 等传统技术区分肌层浸润性膀胱癌和非肌层浸润性膀胱癌。为确保对肿瘤患者采取正确的治疗方法,CEUS 和 DECT 代表了具有特殊优势的新兴模式。本综述最后介绍了正电子发射断层扫描(PET)/CT 和 PET/MRI 等综合成像模式,它们是膀胱癌分期的理想方法。

作者简介

Federica Masino

Foggia University School of Medicine

Email: federicamasino@gmail.com
ORCID iD: 0009-0004-4289-3289

MD

意大利, Foggia

Laura Eusebi

Carlo Urbani Hospital

Email: lauraeu@virgilio.it
ORCID iD: 0000-0002-4172-5126

MD

意大利, Jesi

Gianmichele Muscatella

Foggia University School of Medicine

Email: muscatella94@gmail.com
ORCID iD: 0009-0004-3535-5802

MD

意大利, Foggia

Manuela Montatore

Foggia University School of Medicine

Email: manuela.montatore@unifg.it
ORCID iD: 0009-0002-1526-5047

MD

意大利, Foggia

Giuseppe Sortino

Carlo Urbani Hospital

Email: giuseppesortino@live.it
ORCID iD: 0000-0002-8804-1805

MD

意大利, Jesi

Willy Giannubilo

Civitanova Marche Hospital

Email: willygiannubilo@virgilio.it

MD

意大利, Civitanova Marche

Giuseppe Guglielmi

Foggia University School of Medicine; Dimiccoli Hospital; IRCCS Casa Sollievo della Sofferenza Hospital

编辑信件的主要联系方式.
Email: giuseppe.guglielmi@unifg.it
ORCID iD: 0000-0002-4325-8330

Professor

意大利, Foggia; Barletta; San Giovanni Rotondo

参考

  1. Hill WG. Control of Urinary Drainage and Voiding. Clin J Am Soc Nephrol. 2015;10(3):480–492. doi: 10.2215/CJN.04520413
  2. Glassock RJ, Rule AD. Aging and the Kidneys: Anatomy, Physiology and Consequences for Defining Chronic Kidney Disease. Nephron. 2016;134(1):25–29. doi: 10.1159/000445450
  3. Montatore M, Muscatella G, Eusebi L, et al. Current Status on New Technique and Protocol in Urinary Stone Disease. Curr Radiol Rep. 2023;11(12):1–16. doi: 10.1007/s40134-023-00420-5
  4. Sam P, Nassereddin A, LaGrange CA. Anatomy, Abdomen and Pelvis: Bladder Detrusor Muscle. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
  5. Eusebi L, Masino F, Gifuni R, et al. Role of Multiparametric-MRI in Bladder Cancer. Curr Radiol Rep. 2023;11(5):69–80. doi: 10.1007/s40134-023-00412-5
  6. Nicola R, Pecoraro M, Lucciola S, et al. VI-RADS score system — A primer for urologists. Int Braz J Urol. 2022;48(4):609–622. doi: 10.1590/s1677-5538.ibju.2021.0560
  7. Jubber I, Ong S, Bukavina L, et al. Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors. Eur Urol. 2023;84(2):176–190. doi: 10.1016/j.eururo.2023.03.029
  8. Messina E, Pecoraro M, Pisciotti ML, et al. Seeing is Believing: State of the Art Imaging of Bladder Cancer. Semin Radiat Oncol. 2023;33(1):12–20. doi: 10.1016/j.semradonc.2022.10.002
  9. Compérat E, Amin MB, Cathomas R, et al. Current best practice for bladder cancer: a narrative review of diagnostics and treatments. Lancet. 2022;400(10364):1712–1721. doi: 10.1016/S0140-6736(22)01188-6
  10. Ahmadi H, Duddalwar V, Daneshmand S. Diagnosis and Staging of Bladder Cancer. Hematol Oncol Clin North Am. 2021;35(3):531–541. doi: 10.1016/j.hoc.2021.02.004
  11. Wentland AL, Desser TS, Troxell ML, Kamaya A. Bladder cancer and its mimics: a sonographic pictorial review with CT/MR and histologic correlation. Abdom Radiol. 2019;44(12):3827–3842. doi: 10.1007/s00261-019-02276-w
  12. Wong VK, Ganeshan D, Jensen CT, Devine CE. Imaging and Management of Bladder Cancer. Cancers. 2021;13(6):1396. doi: 10.3390/cancers13061396
  13. Messina E, Pisciotti ML, Pecoraro M, et al. The use of MRI in urothelial carcinoma. Curr Opin Urol. 2022;32(5):536–544. doi: 10.1097/MOU.0000000000001011
  14. Schallom M, Prentice D, Sona C, et al. Accuracy of Measuring Bladder Volumes With Ultrasound and Bladder Scanning. Am J Crit Care. 2020;29(6):458–467. doi: 10.4037/ajcc2020741
  15. Ahmadi H, Duddalwar V, Daneshmand S. Diagnosis and Staging of Bladder Cancer. Hematol Oncol Clin North Am. 2021;35(3):531–541. doi: 10.1016/j.hoc.2021.02.004
  16. Liu Q, Gong H, Zhu H, Yuan C, Hu B. Contrast-Enhanced Ultrasound in the Bladder: Critical Features to Differentiate Occupied Lesions. Comput Math Methods Med. 2021;2021:1–5. doi: 10.1155/2021/1047948
  17. Fouladi DF, Shayesteh S, Fishman EK, Chu LC. Imaging of urinary bladder injury: the role of CT cystography. Emerg Radiol. 2020;27(1):87–95. doi: 10.1007/s10140-019-01739-3
  18. Renard-Penna R, Rocher L, Roy C, et al. Imaging protocols for CT urography: results of a consensus conference from the French Society of Genitourinary Imaging. Eur Radiology. 2020;30(3):1387–1396. doi: 10.1007/s00330-019-06529-6
  19. Abuhasanein S, Hansen C, Vojinovic D, et al. Computed tomography urography with corticomedullary phase can exclude urinary bladder cancer with high accuracy. BMC Urol. 2022;22(1):60. doi: 10.1186/s12894-022-01009-4
  20. Bicci E, Mastrorosato M, Danti G, et al. Dual-Energy CT applications in urinary tract cancers: an update. Tumori. 2023;109(2):148–156. doi: 10.1177/03008916221088883
  21. Parakh A, Lennartz S, An C, et al. Dual-Energy CT Images: Pearls and Pitfalls. RadioGraphics. 2021;41(1):98–119. doi: 10.1148/rg.2021200102
  22. Toia GV, Mileto A, Wang CL, Sahani DV. Quantitative dual-energy CT techniques in the abdomen. Abdom Radiol (NY). 2022;47(9):3003–3018. doi: 10.1007/s00261-021-03266-723
  23. Lai AL, Law YM. VI-RADS in bladder cancer: Overview, pearls and pitfalls. Eur J Radiol. 2023;160:110666. doi: 10.1016/j.ejrad.2022.110666
  24. Panebianco V, Pecoraro M, Del Giudice F, et al. VI-RADS for Bladder Cancer: Current Applications and Future Developments. J Magn Reson Imaging. 2022;55(1):23–36. doi: 10.1002/jmri.27361
  25. Bouchelouche K. PET/CT in Bladder Cancer: An Update. Semin Nucl Med. 2022;52(4):475–485. doi: 10.1053/j.semnuclmed.2021.12.004
  26. Kim SK. Role of PET/CT in muscle-invasive bladder cancer. Transl Androl Urol. 2020;9(6):2908–2919. doi: 10.21037/tau.2020.03.31
  27. Omorphos NP, Ghose A, Hayes JDB, et al. The increasing indications of FDG-PET/CT in the staging and management of Invasive Bladder Cancer. Urol Oncol. 2022;40(10):434–441. doi: 10.1016/j.urolonc.2022.05.017
  28. Zhang-Yin J, Girard A, Marchal E, et al. PET Imaging in Bladder Cancer: An Update and Future Direction. Pharmaceuticals (Basel). 2023;16(4):606. doi: 10.3390/ph16040606
  29. Muin D, Laukhtina E, Hacker M, Shariat SF. PET in bladder cancer imaging. Curr Opin Urol. 2023;33(3):206–210. doi: 10.1097/MOU.0000000000001090

补充文件

附件文件
动作
1. JATS XML
2. 图 1. 膀胱横断面超声图像显示,膀胱壁弥漫性不规则增厚,并伴有多个肿块和腔内发育。最大回声肿块位于左侧膀胱后壁,彩色多普勒成像显示肿瘤内有血管化。

下载 (79KB)
3. 图 2. 矢状切面的对比增强超声图像显示,左侧膀胱壁上有一个体积较大的肿块,在 B 型图像中轮廓不清。

下载 (357KB)
4. 图 3. 多平面碘图像显示多灶性肿块有不同程度的信号衰减,主要肿块位于左后壁。病灶的平均值与腔内值不同。通过光谱曲线(左上),我们可以识别出不同衰减曲线的物质。

下载 (278KB)
5. 图 4. 彩色碘图的多平面图像,显示多灶性肿块有不同程度的信号衰减,主要肿块位于左后壁。病灶的平均值与腔内值不同。通过光谱曲线(左上),我们可以识别出不同衰减曲线的材料。

下载 (515KB)
6. 图 5. 膀胱磁共振成像:a - T2W 模式下的多平面图像显示左侧膀胱后壁一个大于1cm的肿块,中间有肌层信号(VI-RADS 4);b - 扩散加权成像 序列和 测量扩散系数 图显示病变扩散明显受限,并侵入肌层,测量扩散系数 比值低至 0.9×10-3 mm2/s,提示恶性(VI-RADS 4);c - DCE 序列显示病灶早期异质信号放大,并侵入肌肉层(VI-RADS 4)。VI-RADS 总分为 4 分。图片来源:Eusebi Laura, Masino Federica, Gifuni Rossella, Fierro Davide, Michele Bertolotto, Cova Maria Assunta, Giuseppe Guglielmi. Role of Multiparametric-MRI in Bladder Cancer. Current Radiology Reports 11, 69–80 (2023). https://doi.org/10.1007/s40134-023-00412-5. 本文属于公共领域,根据 Creative Commons Attribution (CC BY) 4.0 许可条款发布 (http://creativecommons.org/licenses/by/4.0/)。

下载 (217KB)
7. 图 6. 膀胱磁共振成像: a - T2W 模式下的多平面图像显示,右侧膀胱穹隆外侧壁上有一个超过 1 厘米的肿块,其间有肌肉层信号,并侵入膀胱周围脂肪组织(VI-RADS 5); b - 扩散加权成像 和 测量扩散系数 图显示病变呈明显局限的弥漫性,侵犯肌肉层和膀胱周围脂肪组织(VI-RADS 5);c - DCE 序列显示病变早期不均匀信号增强,侵犯肌肉层和膀胱周围脂肪组织(VI-RADS 5)。VI-RADS 量表的总分是 5 分。图片来源:Eusebi Laura, Masino Federica, Gifuni Rossella, Fierro Davide, Michele Bertolotto, Cova Maria Assunta, Giuseppe Guglielmi. Role of Multiparametric-MRI in Bladder Cancer. Current Radiology Reports 11, 69–80 (2023). https://doi.org/10.1007/s40134-023-00412-5. 本文属于公共领域,根据 Creative Commons Attribution (CC BY) 4.0 许可条款发布 (http://creativecommons.org/licenses/by/4.0/)。

下载 (254KB)

版权所有 © Eco-Vector, 2024

Creative Commons License
此作品已接受知识共享署名-非商业性使用-禁止演绎 4.0国际许可协议的许可。

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).